Home     Archives     Search     Authors     About Us     Subscribe     Contact Us  

Search For:
Search In:

The i2P magazine is distributed by email on a monthly basis. Subscription is free and you can unsubscribe at any time.
Subscribe Here
Unsubscribe Here

If you have any concerns for your privacy, please read our Privacy Policy

- Issue 81: April 2009
- Issue 80: March 2009
- Issue 79: February 2009
- Issue 78: December 2008
- Issue 77: November 2008
- Issue 76: October 2008
- Issue 75: September 2008
- Issue 74: August 2008
- Issue 73: July 2008
- Issue 72: June 2008

More Archives
We are in the process of moving all of our articles to the new site.

In the meantime you can find them on the old i2P site.

The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia. Winstock AR, Lea T, Ritter A. Drug Alc Review 2007 26;4:411-416

Dr Andrew Byrne & Associates
A Harm-Minimisation Research Perspective

Issue 65: October 2007
Page: 1 of 1 Author's Profile | Send to a Friend | Printer Version

Editor's Note:Dr Byrne (and his associates) advocate for better policies which are proven to reduce risks for drug users and the general community under a framework in parallel with Australia's official policy of harm minimization.
The findings of the New South Wales Drug Summit recommend better access to methadone, detoxification and other dependency treatments. It also advised investigating alternative services such as supervised injecting centres, leading to the opening of the Sydney Medically Supervised Injecting Centre in 2001.
Dr Andrew Byrne has been involved in opioid treatments from a primary care background for 20 years at the same site in Redfern, an inner suburb of Sydney.
He is recognised worldwide as a specialist in the addiction field and was involved in the seminal stages of the Chapter of Addiction Medicine, Royal Australasian College of Physicians.
He received the Dole-Nyswander award from the American Association for the Treatment of Opioid Dependence in April 2006.
This month, Dr Byrne comments on the interpretation of survey results from over 400 pharmacists relating to the impact of dispensing fees on a buprenorphine-naloxone service in community pharmacies.

These authors have survey responses from over 400 NSW pharmacists about current and proposed prices for methadone and buprenorphine under various regimens including daily, weekly, fortnightly and monthly attendance. 
A figure of $31 weekly recurs with little variation according to the number of attendances until this reached one per fortnight when the lowest response was $19 per week.   
These authors do not examine these fees in relation to other commercial aspects of community pharmacy, nor are we given an international comparison. 
Ideally, as with other medical treatments, those who are unemployed or indigent should be looked after in the public system.
In many areas there is simply no alternative to pharmacy treatment since most hospital pharmacies steadfastly refuse to become involved. 
In the 1980s, the published recommended price in NSW was $5 daily ‘including counselling’ ($35 per week). 
Pharmacists still charge approximately the same price which is a philanthropy without parallel in health care in my experience.   
The authors state that the introduction of the bup-naloxone combination product:
“permitted the revision of takeaway policies … and … the possibility of unsupervised treatment.” 
Only one of the 24 references refers to the combination product which hardly supports the contention that this constitutes a ‘new treatment paradigm’. 

They suggest a need for:
“early dissemination of unambiguous information regarding the introduction of a new medication, especially where supervised dispensing through community pharmacies is essential to the provision of treatment.
The potential impact upon the successful rollout of a new treatment paradigm that was developed to benefit stable patients in the community may be jeopardised when such processes are not followed.”   

I would suggest that the only thing jeopardising this new treatment paradigm being rolled-out (hate those terms!) is a lack of evidence that it actually works in practice!
There is a dearth of research on both the combination product itself and on (completely) non-supervised treatment such as is commonly used in France and England. 
This all makes the tone of the paper somewhat confusing since the benefits proposed for buprenorphine-naloxone are still theoretical. 

These authors appear to believe that long term dispensing or administration of buprenorphine should be cheaper than traditional short term maintenance treatments and they seem disappointed with outcomes showing otherwise, at least for less than fortnightly attendance. 
 It is hard to be ‘unambiguous’ about a new and untried treatment, and pharmacists of all people, know that dealing with addictions can be tough and unpredictable. 
Also, the new proposal assumes that doctors are able to distinguish which patient is going to be stable long term, yet there is no simple way I know of doing that.  
The best protection for patients may be the innate conservatism of Australian health care workers, sceptical of claims made for new drugs until proven in practice.
It is indeed a ‘brave new world’, giving addicted patients medication without the continuing supervision of a pharmacist, nurse, psychologist or even a self-help or group therapy session.  In fact, this ‘paradigm’ flies in the face of the DSM definition of addiction, involving some degree of loss of control over drug use at certain times. 
Another concern was borne out in a paper from Melbourne recently (Neilsen 2007) where administering buprenorphine as a sub-lingual tablet was associated with numerous reported practical problems compared with the use of liquid methadone. 
I wonder how many Australian doctors are prescribing unsupervised buprenorphine. 

 Comments by Andrew Byrne .. 

Nielsen S, Dietze P, Dunlop A, Muhleisen P, Lee N, Taylor D. Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified. Drug Alc Review 2007 26;2:143-

Back to Top | Back to Home
Copyright © Computachem Services, All Rights Reserved. Published by Computachem Services, PO Box 297 Alstonville 2477 NSW Australia